Literature DB >> 2665972

Effects of recombinant human tumor necrosis factor alpha, lymphotoxin, and Escherichia coli lipopolysaccharide on hemodynamics, lung microvascular permeability, and eicosanoid synthesis in anesthetized sheep.

E A Kreil1, E Greene, C Fitzgibbon, D R Robinson, W M Zapol.   

Abstract

We infused recombinant human tumor necrosis factor alpha (rhTNF alpha), lymphotoxin (rhLT), and Escherichia coli 0111:B4 lipopolysaccharide (LPS) into anesthetized sheep with a lung lymph fistula to compare their effects on systemic and pulmonary hemodynamics, lung lymph dynamics, and eicosanoid release. rhTNF alpha (25-150 micrograms/kg, n = 6 sheep), but not rhLT (25 micrograms/kg, n = 3), rapidly increased lung lymph and plasma levels of 6-keto-prostaglandin F1 alpha (6-k-PGF1 alpha) and caused profound systemic vasodilation and hypotension. Meclofenamate pretreatment (10 mg/kg) of three other sheep given 25 micrograms/kg rhTNF alpha prevented the increase of lymph and plasma 6-k-PGF1 alpha levels, systemic vasodilation, and the early (less than 2 hrs) but not the late (4-6 hours) hypotension caused by rhTNF alpha. LPS (1 micrograms/kg, n = 11) induced a briefer increase of lymph 6-k-PGF1 alpha levels than did rhTNF alpha while plasma 6-k-PGF1 alpha levels did not increase. LPS induced more gradual hypotension than did rhTNF alpha but did not cause systemic vasodilation. LPS and rhTNF alpha, but not rhLT, increased lymph thromboxane B2 (TXB2) levels during the first hour of study, whereas only LPS acutely increased plasma TXB2 levels. LPS caused acute pulmonary vasoconstriction and greater acute pulmonary artery hypertension than did either rhTNF alpha or rhLT. Whereas LPS-treated sheep required less fluid transfusion than rhTNF alpha-treated sheep to maintain mean systemic arterial pressure greater than 50 mm Hg, LPS infusion caused a greater increase of lung lymph protein clearance. rhTNF alpha caused minimal alterations of lung microvascular permeability. We conclude that eicosanoid mediators contribute importantly to differences of systemic and pulmonary hemodynamics caused by these agents in sheep. rhTNF alpha cannot account for all of the LPS-induced hemodynamic, lung lymph, and eicosanoid responses in sheep.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2665972     DOI: 10.1161/01.res.65.2.502

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  6 in total

1.  Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs.

Authors:  F D Pagani; L S Baker; C Hsi; M Knox; M P Fink; M S Visner
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

2.  Attenuation of shock-induced inflammation in the rat liver depends on the time of TNF-alpha inhibition.

Authors:  C Bauer; W Roth; S Bahrami; I Marzi
Journal:  J Mol Med (Berl)       Date:  1996-01       Impact factor: 4.599

3.  HA-1A in septic patients with ARDS: results from the pivotal trial.

Authors:  L M Bigatello; R E Greene; C L Sprung; E A Panacek; R C Straube; J L Zimmerman; R J Maunder; P N Lanken; E Pile-Spellmann; K S Stanek
Journal:  Intensive Care Med       Date:  1994-05       Impact factor: 17.440

4.  Acute metabolic effects of human recombinant tumor necrosis factor beta in the rat.

Authors:  D Blumberg; A Tsuburaya; M Burt; D B Donner; M F Brennan
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

5.  Human lymphotoxin mutein lacks hypotensive activity but has higher in vivo antitumor activity than lymphotoxin or tumor necrosis factor.

Authors:  M Taniyama; T Morita; Y Yamagishi; A Kato; C Bando; N Okawa; A Kaji
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

6.  Impaired Glucocorticoid Receptor Dimerization Aggravates LPS-Induced Circulatory and Pulmonary Dysfunction.

Authors:  Martin Wepler; Jonathan M Preuss; Tamara Merz; Clair Hartmann; Ulrich Wachter; Oscar McCook; Josef Vogt; Sandra Kress; Michael Gröger; Marina Fink; Angelika Scheuerle; Peter Möller; Enrico Calzia; Ute Burret; Peter Radermacher; Jan P Tuckermann; Sabine Vettorazzi
Journal:  Front Immunol       Date:  2020-01-23       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.